Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
← catalyst calendarSponsored by Aligos Therapeutics (industry) · ALGS — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
16estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-30 | actual | When the study began enrolling |
| Primary completion | 2026-04-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Hepaititis B Infections
Intervention
- Drug: Pevifoscorvir Sodium (ALG-000184)
Primary outcomes
what the primary-completion date above is the date OFArea under the concentration time curve [AUC]
measured Up to 4 days
Time to maximum plasma concentration [Tmax]
measured Update to 4 Days
Maximum plasma concentration [Cmax]
measured Update to 4 days
Minimum plasma concentration [Cmin]
measured Up to 4 days
C0 (predose)
measured Up to 4 days
Half-life [t1/2]
measured Up to 4 Days
Permalink · ALGS's whole pipeline · Catalyst calendar · Every registered study · What changed